SCP
VKTX icon

Sender Company & Partners’s Viking Therapeutics VKTX Stock Holding History

Sender Company & Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
53,800
+27,900
+108% +$897K 1.06% 22
2025
Q4 		$911K Buy
+25,900
New +$918K 0.42% 46
2025
Q3 		– Sell
-57,600
Closed -$1.53M – 596
2025
Q2 		$1.53M Buy
+57,600
New +$1.52M 0.43% 65

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Sender Company & Partners's VKTX Position: Q1 2026 in Review

Sender Company & Partners reduced its Viking Therapeutics (VKTX) stake by 19% in Q1 2026, selling an estimated $119K and leaving 16,136 shares worth $525K. The position accounts for 0.32% of the portfolio, ranked #36.

Sender Company & Partners first reported a position in VKTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $698K in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Sender Company & Partners held 16,136 shares of Viking Therapeutics worth $525K as of Q1 2026.
  • Sender Company & Partners sold 3,700 Viking Therapeutics shares in Q1 2026, an estimated $119K.
  • Viking Therapeutics made up 0.32% of Sender Company & Partners's portfolio in Q1 2026, its #36 holding.
  • Sender Company & Partners first reported a position in Viking Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Sender Company & Partners's Viking Therapeutics position peaked at $698K in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Sender Company & Partners's 13F filing for Q1 2026, filed 15 May 2026.